Form 4: Zentalis Pharmaceuticals Director Receives Stock Grant

Zentalis Pharmaceuticals, Inc. reports a grant of restricted stock units to Director Shannon Campbell.

Summary

• Shannon Campbell, a Director at Zentalis Pharmaceuticals, Inc., was granted 114,200 shares of Common Stock on May 26, 2026.
• This grant was made under the Issuer's Non-Employee Director Compensation Program.
• The restricted stock units (RSUs) will vest in three equal tranches on the first, second, and third anniversaries of the grant date, contingent upon continued service.
• The reported transaction is a grant of securities, not a purchase or sale, with a reported value of $0 at the time of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to standard director compensation and does not provide new financial performance data or strategic updates.

Positives

• Director compensation through equity awards aligns the interests of management with shareholders.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The filing does not provide specific financial performance data, making it difficult to assess the immediate impact on the company's financial health.

Risks

• The value of the granted RSUs is subject to market fluctuations and the company's future performance.
• Continued service is a condition for vesting, implying a risk of forfeiture if the director's tenure ends before vesting dates.

Future Outlook

The future outlook is not directly addressed in this filing, which focuses on a director's equity grant. Vesting of the RSUs is tied to continued service over the next three years.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biopharmaceutical industry to attract and retain experienced leadership, aligning their incentives with long-term company success.

Comparison to Industry Standards

• The structure of this RSU grant, with vesting over three years and contingent on continued service, is a common practice among publicly traded companies, particularly in the life sciences sector.
• Many companies, including competitors of Zentalis Pharmaceuticals, utilize similar compensation programs to incentivize board members and key executives.

Related Party Transactions

• The grant of restricted stock units to Director Shannon Campbell is a related party transaction, as per the Issuer's Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The grant represents an issuance of equity, which could dilute ownership slightly if fully vested and exercised, but also aligns director incentives with shareholder value.
• Employees: No direct impact is indicated for general employees.
• Management: Reinforces standard compensation practices for non-employee directors.

Next Steps

• Vesting of one-third of the RSUs on the first anniversary of the grant date (May 26, 2027), subject to continued service.
• Vesting of the second third of the RSUs on the second anniversary of the grant date (May 26, 2028), subject to continued service.
• Vesting of the final third of the RSUs on the third anniversary of the grant date (May 26, 2029), subject to continued service.

Key Dates

Keywords

Zentalis Pharmaceuticals, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, Equity Grant, Shannon Campbell, ZNTL